Plus Therapeutics (PSTV) Equity Average (2011 - 2026)
Plus Therapeutics (PSTV) reported Equity Average of $8.0 million for Q1 2026, up 148.96% year-over-year from $3.2 million in Q1 2025, and up 76.32% quarter-over-quarter from $4.5 million in Q4 2025.
Plus Therapeutics (PSTV) Equity Average (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 16 years of Equity Average data on file, last reported at $8.0 million in Q1 2026.
- Equity Average for Q1 2026 came in at $8.0 million, up 148.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 148.96% YoY), and the FY2025 annual result was -$2.5 million, up 51.9% from the prior year.
- Equity Average advanced to $8.0 million in Q1 2026 per PSTV's latest filing, from $4.5 million in the prior quarter.
- Over five years, Equity Average peaked at $12.7 million in Q1 2022 and troughed at -$16.3 million in Q1 2025.
- A 5-year average of $1.3 million and a median of $2.7 million in 2023 frame the typical range for Equity Average.
- The sharpest annual moves came in 2024 and 2025: Equity Average plunged 1208.56% in 2024, then soared 164.08% in 2025.
- A 5-year view of Equity Average shows it stood at $8.9 million in 2022, then sank by 92.86% to $637000.0 in 2023, then sank by 1208.56% to -$7.1 million in 2024, then surged by 164.08% to $4.5 million in 2025, then surged by 76.32% to $8.0 million in 2026.
- Business Quant data shows PSTV's Equity Average at $8.0 million in Q1 2026, $4.5 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 516.41 Mn |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | 7.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.98 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | -16.30 Mn |
| Dec 31, 2024 | -7.06 Mn |
| Sep 30, 2024 | -6.40 Mn |
| Jun 30, 2024 | -6.23 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | 637,000.00 |
| Sep 30, 2023 | 2.64 Mn |
| Jun 30, 2023 | 2.67 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 8.92 Mn |
| Sep 30, 2022 | 10.54 Mn |
| Jun 30, 2022 | 12.16 Mn |
| Mar 31, 2022 | 12.74 Mn |
| Dec 31, 2021 | 12.80 Mn |
| Sep 30, 2021 | 13.35 Mn |
| Jun 30, 2021 | 10.73 Mn |